REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $10.15. Don't Miss ...
Across the recent three months, 5 analysts have shared their insights on Regenxbio RGNX, expressing a variety of opinions ...
GET MORE AI-GENERATED SIGNALS: November 14, 2024, 18:38 pm ET, BY Tyler- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
RegenXBio Inc. ( (RGNX)) has released its Q3 earnings. Here is a breakdown of the information RegenXBio Inc. presented to its investors. RegenXBio Inc. is a clinical-stage biotechnology company ...
Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago. These figures are ...
Cash Runway Guidance: Expected to fund operations into 2026. Regenxbio Inc (NASDAQ:RGNX) is making significant progress in ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
Regenxbio: Q3 Earnings Snapshot ...
ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Wednesday reported a loss of $59.6 million in its third quarter. On a per-share basis, the Rockville, Maryland-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback